Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: A network meta-analysis of different injection treatments

Hong Pan, Yu Zheng, Saroj Rai, Yuhong Ding, Yeming Zhou, Ruikang Liu, Jin LiFrontiers in Pharmacology 2022 · DOI

TL;DR

This network meta-analysis of 19 randomized controlled trials (1,066 patients) evaluates the efficacy of various injection treatments for Carpal Tunnel Syndrome (CTS). The study finds that while 5% dextrose and hydroxyprogesterone show surprising strengths, Platelet-Rich Plasma (PRP) is a highly effective and safe alternative, consistently ranking as a top-tier treatment for pain, symptom severity, and functional recovery.

What Problem Does This Paper Address?

Carpal Tunnel Syndrome (CTS) is the most common form of peripheral nerve compression, often leading to pain, numbness, and loss of hand function. While corticosteroid injections are the current "gold standard" for non-surgical management, they aren't a silver bullet; roughly 75% of patients receiving steroids still require surgery within a year. Furthermore, steroids carry risks of local tissue damage.

Clinicians have explored several alternatives—including Platelet-Rich Plasma (PRP), dextrose (prolotherapy), and even hormonal injections like hydroxyprogesterone—but until now, there hasn't been a comprehensive "head-to-head" comparison to determine which of these diverse treatments actually works best.

Methods

The authors performed a Network Meta-Analysis (NMA). Unlike a standard meta-analysis that only compares two treatments (e.g., PRP vs. Placebo), an NMA allows researchers to compare multiple treatments simultaneously, even if they haven't been directly compared in a single trial, by using a common comparator (usually a placebo).

Key technical details: * Search Scope: Five major databases (Medline, Embase, etc.) were searched through October 2022. * Inclusion: Only Randomized Controlled Trials (RCTs) were included. * Ranking Algorithm: The researchers used SUCRA (Surface Under the Cumulative Ranking) values. SUCRA is a numeric representation (0 to 100%) of the probability that a treatment is the "best" among all options. * Outcomes: They measured three validated scales: Visual Analog Scale (VAS) for pain, Symptom Severity Scale (SSS), and Functional Status Scale (FSS).

Datasets

The study synthesized data from 19 RCTs involving a total of 1,066 patients. The treatments analyzed included:

  • Platelet-Rich Plasma (PRP)
  • Corticosteroids (Triamcinolone, Methylprednisolone, Dexamethasone, Betamethasone)
  • 5% Dextrose (Dex)
  • Hydroxyprogesterone (Hyd)
  • Piroxicam (NSAID)
  • Ozone (Soz)
  • Placebo (Pla)

Key Insights and Ideas

  • The "Growth Factor" Advantage: The core hypothesis for PRP's success is its high concentration of autologous growth factors (like PDGF and VEGF), which may actively promote the healing of the median nerve rather than just suppressing inflammation like steroids.
  • The Dextrose Surprise: 5% dextrose ranked highest for pain reduction (VAS). This is likely due to "prolotherapy" effects, where the solution may help decompress the nerve mechanically or modulate pain receptors.
  • Hormonal Influence: Hydroxyprogesterone emerged as a powerhouse for improving symptom severity and hand function. This highlights the significant role hormonal imbalances (often seen in pregnancy or menopause) play in CTS pathology.
  • Safety Profile: A major "aha moment" was the safety data. While steroids have known side effects, no serious complications were reported across the PRP studies, making it a "high-reward, low-risk" option.

Key Results

The SUCRA rankings (where higher % = better performance) revealed a nuanced leaderboard:

  • Pain Reduction (VAS):
    1. 5% Dextrose (79.2%)
    2. High-dose Triamcinolone (62.7%)
    3. PRP (60.0%)
  • Symptom Severity (SSS):
    1. Hydroxyprogesterone (91.0%)
    2. PRP (60.8%)
  • Functional Status (FSS):
    1. Hydroxyprogesterone (99.5%)
    2. Low-dose Triamcinolone (87.4%)
    3. PRP (77.1%)

Quantitative Highlight: For pain (VAS), 5% dextrose showed a Mean Difference (MD) of -1.22 compared to placebo, while PRP showed an MD of -0.39. However, PRP's consistent top-3 ranking across all categories makes it the most versatile "all-rounder."

Limitations and Future Work

  • Short-Term Focus: The analysis was limited to short-term outcomes (up to 12 weeks). The long-term durability of PRP vs. steroids remains an open question.
  • PRP Heterogeneity: There is no "standard recipe" for PRP. Differences in platelet concentration and preparation methods across the 19 studies could introduce variability in results.
  • Sample Size: While 1,066 patients is a solid start, some specific treatment arms (like hydroxyprogesterone) were based on fewer studies, requiring more data to confirm their high rankings.
  • Future Direction: The authors suggest more large-scale, long-term RCTs are needed to establish standardized protocols for PRP dosage and frequency.

Summary updated

Abstract

<b>Purpose:</b> Carpal tunnel syndrome (CTS) is a common form of median nerve compression in the wrist caused by focal peripheral neuropathy. Platelet-rich plasma (PRP) therapy could improve the healing ability by exposing the injured tissues to high concentrations of autologous growth factors. Our study aims to compare all injective treatments for CTS and assess the efficacy and priority of PRP therapy. <b>Methods:</b> We searched Medline, Embase, Web of Science, Cochrane databases, and Clinicaltrial.gov until 17 October 2022. We only included data from randomized controlled trials (RCTs) that evaluated PRP injection therapy or drug injection therapy. The included RCTs measured at least one of the following three outcomes with validated instruments: in the visual analog scale (VAS), symptom severity scale (SSS), and functional status scale (FSS). <b>Results:</b> Overall, 19 studies with 1,066 patients were included in this study. We used the SUCRA rankings to determine the merits of various therapies. In all, 5% dextrose injections were the best treatment strategy for the VAS (MD -1.22, 95% CI -2.66 to 0.23; SUCRA = 79.2%), followed by triamcinolone (high-dose) injections (MD -0.69, 95% CI -2.11 to 0.73; SUCRA = 62.7%) and PRP injections (MD -0.39, 95% CI -1.67 to 0.89; SUCRA = 60.0%). In the SSS, the most effective intervention was hydroxyprogesterone injections (MD -0.62, 95% CI -1.09 to -0.16; SUCRA = 91.0%). The SUCRA ranking of PRP was second only to steroids and estrogen (MD -0.39, 95% CI -0.60 to -0.18; SUCRA = 60.8%). In the FSS, the best regimen strategy was hydroxyprogesterone injections (MD 0.12, 95% CI -0.30 to 0.54; SUCRA = 99.5%), followed by triamcinolone (low-dose) injections (MD -0.02, 95% CI -0.54 to 0.49; SUCRA = 87.4%) and PRP injections (MD -0.26, 95% CI -0.43 to -0.09; SUCRA = 77.1%). <b>Conclusion:</b> PRP is an alternative choice for CTS treatment. PRP injection is second only to steroids and estrogen in the treatment efficacy of CTS, with a wide indication and safe outcome.
BibTeX
@inproceedings{pan2022efficacy,
  author = {Hong Pan and Yu Zheng and Saroj Rai and Yuhong Ding and Yeming Zhou and Ruikang Liu and Jin Li},
  title = {{Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: A network meta-analysis of different injection treatments}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.906075},
}
Figure